media – Page 426 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Severe COVID-19 linked to age, body mass index and ABO blood group

With the COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecting over 50 million people worldwide with hundreds of thousands experiencing severe respiratory illness, researchers have been trying to find the factors associated with severe disease. From the start of the pandemic in March this year, several studies have indicated heart disease, high blood pressure, diabetes, obesity, etc. could be linked to severe disease. Now German researchers have published a study on the association between severe respiratory infection caused by SARS CoV-2 and factors such as age, body mass index (BMI) and ABO blood group. Their study titled, “Severity of Respiratory Infections due to SARS-CoV-2 in Working Population: Age and Body Mass Index Outweigh ABO Blood Group,” was released prior to peer review on the preprint site medRxiv*. Background There is a rise in cases of COVID-19, and there is a lack of consensus regarding the high-risk ...
- Source: drugdu
- 125
- November 13, 2020
Covid-19
Spain’s annual life expectancy at birth dropped due to COVID-19 pandemic

Spain’s annual life expectancy at birth dropped by 0.9 years between 2019 and the annual period up until July 2020 due to the COVID-19 pandemic, according to a new study published this week in the open-access journal PLOS ONE by Sergi Trias-Llimos of the Center for Demographic Studies, Spain, and colleagues. The COVID-19 pandemic is causing substantial increases in mortality in populations worldwide, and Spain was one of the most affected countries in the spring of 2020. Life expectancy is an easy to interpret, standard indicator in mortality patterns. However, few studies assessing the impact of the pandemic on mortality to date have reported life expectancy estimates. In the new study, researchers used daily death count data from the Spanish Daily Mortality Monitoring System (MoMo) as well as information on death, population and demographic information from the Spanish National Statistics Institute. The team estimated weekly and annual life expectancies at birth for ...
- Source: drugdu
- 349
- November 12, 2020
Covid-19
Anvisa suspende temporariamente teste da vacina CoronaVac, que será produzida pelo Butantan

Interrupção foi determinada após ‘evento adverso grave’, segundo a agência. Em entrevista à TV Cultura, diretor do Butantan disse que a morte do voluntário não teve relação com o teste. A Agência Nacional de Vigilância Sanitária (Anvisa) suspendeu temporariamente os testes em humanos da vacina CoronaVac contra a Covid-19. De acordo com a agência, a interrupção foi determinada nesta segunda-feira (9) por causa de um “evento adverso grave”, mas não deu detalhes sobre a causa específica da suspensão. A Anvisa informou que foi notificada do “evento” em 29 de outubro. Mais de 10 dias depois, determinou que nenhum novo voluntário poderá ser vacinado até que a agência possa avaliar os dados e “julgar o risco/benefício da continuidade do estudo”. Segundo uma lista divulgada pela agência, são considerados eventos adversos graves “morte, evento adverso potencialmente fatal, incapacidade ou invalidez persistente, internação hospitalar do paciente, anomalia congênita ou defeito de nascimento, qualquer suspeita de transmissão ...
- Source: drugdu
- 399
- November 11, 2020
Covid-19 vaccine
PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED SUCCESS IN FIRST INTERIM ANALYSIS FROM PHASE 3 STUDY

Monday, November 09, 2020 – 06:45am Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis Analysis evaluated 94 confirmed cases of COVID-19 in trial participants Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005539/en/ NEW YORK & MAINZ, GERMANY–(BUSINESS WIRE)– Pfizer Inc. (NYSE: ...
- Source: drugdu
- 1,240
- November 10, 2020
Covid-19 Pfizer
FDA warns of COVID-19 antigen test false positives as report flags Quidel on accuracy

FDA has issued an alert to clinical labs and healthcare providers about the potential for COVID-19 antigen tests to deliver false positives after receiving reports from nursing homes and other settings. The agency’s Tuesday notice reminds users to follow the instructions, noting that improper storage and reading the results at the wrong time can lead to false results. At the same time, the agency said false positives could be an inevitable consequence of using tests with specificities below 100%. If a test with 98% specificity is used to screen a population in which 10% of people are infected, two out of every 10 positive results will be false. The FDA’s warning comes a day after The New York Times reported on a University of Arizona study raising concerns about the ability of a Quidel rapid antigen test to detect asymptomatic cases. The study found Quidel’s test produced more false positives than positives confirmed by the gold standard PCR tests. The potential for antigen tests ...
- Source: drugdu
- 392
- November 9, 2020
Covid-19
COVID-19 lockdowns increase the number of polio cases in Pakistan

A spike in the number of polio cases in Pakistan — the last refuge of the virus in the world along with neighbouring Afghanistan — is being attributed by health experts to disruption in vaccination services caused by lockdowns and restrictions against spread of the COVID-19 pandemic. “The increase in polio cases could result in the global export of infections and healthcare authorities must intensify efforts to track and vaccinate unvaccinated children, says Misbahud Din, researcher in molecular biology and immunology at Quaid-i-Azam University, Islamabad and lead author of a study, published October online in Public Health, on polio vaccination disruptions due to COVID-19 in Pakistan. Din tells SciDev.Net that “80 cases of wild polio virus (WPV) and 64 cases of circulating vaccine-derived poliovirus (cVDPV) have been reported in 2020”. According to the study, around 40 million children missed polio vaccination after Pakistan, on 26 March, suspended a mass vaccination programme being carried ...
- Source: drugdu
- 222
- November 8, 2020
Covid-19
Rapid rise in CRP levels predicts COVID-19 outcomes

Predicting the course of a COVID-19 patient’s disease after hospital admission is essential to improving treatment. Brigham and Women’s Hospital researchers analyzed patients’ levels of inflammation, known to be associated with severity of illness, by looking at C-reactive protein (CRP) trends in 100 COVID-19 patients admitted to the hospital. They found that a rapid rise in CRP levels during the first 48-to-72 hours of hospitalization was predictive of subsequent respiratory deterioration and intubation, while steadier CRP levels were observed in patients whose condition remained stable. Findings were published in Cell Reports Medicine. We realized that whereas a single CRP lab value from hospital admission wasn’t very practical as a predictor of who might get sicker, tracking the rate of change from Day 1 to Day 2 or 3 was a very powerful and very clinically predictive test. Even though all of these patients looked clinically similar upon admission, as early as ...
- Source: drugdu
- 350
- November 7, 2020
Covid
Fujifilm acquisition of Hitachi diagnostic imaging business delayed by COVID-19

Fujifilm Corporation’s planned $1.63 billion acquisition of Hitachi’s diagnostic imaging business has been put on hold in the midst of the ongoing COVID-19 pandemic. The Japanese healthcare giants, which began discussing the deal back in December, were aiming to complete the acquisition some time in July. Fujifilm, however, now says that “delays in some of the preparations” brought on by the spread of the virus have changed the completion schedule and that both parties will need more time to hammer out and finalize the details. “Due to the spread of CIVD19 globally, preparations for regulatory laws related to matters and clearance for anti-monopoly have been delayed. Government offices, legal offices and others impacted by lock downs and stay at home measures have slowed these activities,” Dave Wilson, director of communications for Hitachi Healthcare Americas, told HCB News. Fujifilm has delayed a planned acquisition of Hitachi’s diagnostic imaging-related business due to the ...
- Source: drugdu
- 309
- November 6, 2020
Covid-19
Argentina agrees to buy 25 million doses of Russia’s Covid-19 vaccine

President Fernández reveals in interview with Russian news agency that government will receive initial 10 million doses of Sputnik V vaccine by as early as December, should it clear clinical trials. resident Alberto Fernández said Monday that Argentina has accepted a proposal from Russia to buy an initial 10 million doses of its experimental Covid-19 vaccine, with delivery expected before the end of the year. The vaccine, which is given in two parts, could even arrive as early as next month provided clinical trials are successful, the president said in an interview with a Russian news agency. If successful, another 15 million doses could arrive in January, he added. The news comes just days after Perfil journalist Rosario Ayerdi revealed that Health Access Secretary Carla Vizzotti had travelled to Russia on October 17 on a fact-finding mission to learn more about the Russian vaccine, known as Sputnik V. Fernández confirmed Vizzotti’s ...
- Source: drugdu
- 302
- November 5, 2020
Covid-19 vaccine
Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer

Only HER2-directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for previously treated patients in this setting AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for the treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that offer significant advances over available options by demonstrating safety or efficacy improvements, preventing serious conditions, or enhancing patient compliance. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, will be during the first quarter of 2021. There are more than 27,000 new cases of gastric cancer in the US each year, of which approximately one in five are HER2 positive.1,2 For patients with metastatic gastric cancer who progress ...
- Source: drugdu
- 319
- November 4, 2020
gastric cancer

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.